NCT04435106

Compassionate Use of Opaganib in Patients With Coronavirus Disease 2019 (COVID-19)

Compassionate Use of Opaganib in Patients With Severe COVID-19

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 23 (actual)
• Sponsor: Shaare Zedek Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: —

Summary

Shaare-Zedek Medical Center is a tertiary academic hospital in Jerusalem, Israel. On March 2020, a dramatic increase in the number of COVID-19 cases were diagnosed in Jerusalem. RedHill Biopharma, Ltd. offered opaganib under compassionate use for the treatment of COVID-19 patients. Eligible patients were those hospitalized with COVID-19 confirmed by a reverse-transcriptase-polymerase-chain-reaction assay. Patients received opaganib and Standard of Care. For the purpose of this study, the opaganib and Standard of Care patient group was compared to a group of patients that received only Standard of Care. Opaganib is an investigational drug under development and not approved for commercial distribution.

Detailed description

In this observational study, the two cohorts were assigned retrospectively. Patients either received opaganib and Standard of Care (SOC) or SOC only. All patients were defined by the treating physicians at baseline as severe COVID-19. For the control cohort, IRB approval was granted to collect de-identified data. Both cohorts had similar median age and similar rates of diabetes, hypertension and obesity. The two treatment groups, opaganib and SOC vs. SOC were then analyzed for their clinical outcomes including baseline characteristics.

Conditions

• Coronavirus Infections

Interventions

Type	Name	Description
DRUG	Opaganib	Study participants received opaganib 2 x 250 mg capsules (500 mg) every 12 hours in addition to Standard of Care
DRUG	Standard of Care	Study participants received Standard of Care

Timeline

• Start date: 2020-04-03
• Primary completion: 2020-05-01
• Completion: 2020-05-15
• First posted: 2020-06-17
• Last updated: 2020-06-17

Locations

1 site across 1 country: Israel